Skip to content

Immulite 2500 Automated Immunoassay Analyzer

by Diagnostic Products Corp.

510(k) K033234

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None ongoing

3 closed

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK033234 Date12 Dec 2003ClearedStatusActive

Recalls

3 recalls · FDA

    • Terminated Z-1033-2010 FDA Unclassified (pre-2012) initiated 21 Oct 2009 on shared 510(k) K033234

    The recall was initiated because Siemens Healthcare Diagnostics has identified there is the potential for patient results to be biased low (-0.3 Sample to Cutoff [S/CO] ratio units) due to incompatibility of the Toxoplasma IgM kits with this particular lot of IgG/IgM Sample Diluent. All available lots of the IMMULITE 2000/2500 Toxoplasma IgM kits (L2KTM/L5KTM) are incompatible with Diluent lot 150

    • Terminated Z-1399-2009 FDA Unclassified (pre-2012) initiated 5 Jan 2009 on shared 510(k) K033234

    Design Flaw: The redesign of the Digital Fluidics PCB used in IMMULITE 2000 and IMMULITE 2500 is missing a jumper.

    • Terminated Z-0263-05 FDA Unclassified (pre-2012) initiated 29 Oct 2004

    Erroneous handling of samples will cause problems after the system is placed in 'Sample-pause'.

Recalls on a shared submission name another device cleared under the same FDA submission as this one.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DHA
Device Class
Class II
Regulation
21 CFR Part 862.1155
Advisory Committee
Clinical Chemistry
FDA Decision
SESE Substantially Equivalent

Other devices from Diagnostic Products Corp.

See all devices from Diagnostic Products Corp. →